Irbesartan/Hydroklortiazid Actavis (Hydrochlorothiazide, Irbesartan)

The combination works by two mechanisms: Irbesartan blocks the AT1 receptor, preventing angiotensin II‑driven vasoconstriction and aldosterone release, while Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal tubule, increasing urine output and reducing blood volume. Together they lower peripheral resistance and intravascular volume, resulting in blood‑pressure reduction.

The appropriate dose is individualized by the prescribing clinician based on the patient’s blood‑pressure level, renal function, electrolyte status, and response to therapy. Dosage adjustments may be required for elderly patients or those with impaired kidney function, and the prescriber will decide the exact strength and frequency.

Irbesartan/Hydrochlorothiazide is generally contraindicated in the second and third trimesters of pregnancy because of potential fetal toxicity. Safety during breastfeeding has not been established, and clinicians usually advise against its use in nursing mothers unless the benefits clearly outweigh the risks.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy agents, the Irbesartan/Hydrochlorothiazide combo offers additive blood‑pressure lowering effects, often achieving target control with a single pill. It may be preferred over separate tablets for convenience and adherence. Relative to other ARB‑diuretic combinations, efficacy and safety are comparable, but individual patient factors such as electrolyte balance guide the choice.

Store the tablets at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

The medication is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed. Consistent timing each day helps maintain stable blood‑pressure control.

Serious adverse events include severe hypotension, acute kidney injury, hyperkalemia, significant electrolyte disturbances (such as hyponatremia), and rare allergic reactions like angioedema. Patients should be monitored for sudden dizziness, reduced urine output, swelling, or rash, and seek medical attention promptly if these occur.

The combination is contraindicated in patients with known hypersensitivity to Irbesartan, Hydrochlorothiazide, or any component of the formulation. It should also be avoided in individuals with severe renal impairment, hyperkalemia, or in the second and third trimesters of pregnancy. Clinicians must assess each patient’s medical history before initiating therapy.